home / stock / repl / repl quote
Last: | $8.09 |
---|---|
Change Percent: | 0.0% |
Open: | $8.5 |
Close: | $8.09 |
High: | $8.5 |
Low: | $7.95 |
Volume: | 519,616 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.09 | $8.5 | $8.09 | $8.5 | $7.95 | 519,616 | 07-04-2024 |
$8.09 | $8.5 | $8.09 | $8.5 | $7.95 | 519,616 | 07-03-2024 |
$8.37 | $9.3 | $8.37 | $9.37 | $8.18 | 921,916 | 07-02-2024 |
$9.36 | $8.98 | $9.36 | $9.49 | $8.83 | 1,161,299 | 07-01-2024 |
$9 | $8.55 | $9 | $9 | $8.3 | 1,784,172 | 06-28-2024 |
$8.52 | $8.7 | $8.52 | $8.79 | $8.33 | 523,254 | 06-27-2024 |
$8.71 | $8.78 | $8.71 | $8.82 | $8.42 | 875,431 | 06-26-2024 |
$8.82 | $8.71 | $8.82 | $9.005 | $8.54 | 846,830 | 06-25-2024 |
$8.76 | $8.47 | $8.76 | $9.11 | $8.47 | 1,059,108 | 06-24-2024 |
$8.5 | $7.9 | $8.5 | $8.86 | $7.86 | 9,777,100 | 06-21-2024 |
$7.87 | $7.69 | $7.87 | $7.94 | $7.31 | 1,444,899 | 06-20-2024 |
$7.64 | $7.8 | $7.64 | $7.91 | $7.45 | 1,411,556 | 06-19-2024 |
$7.64 | $7.8 | $7.64 | $7.91 | $7.45 | 1,411,556 | 06-18-2024 |
$7.81 | $8.27 | $7.81 | $8.27 | $7.31 | 3,033,726 | 06-17-2024 |
$8.365 | $9.43 | $8.365 | $9.5495 | $8.315 | 1,583,489 | 06-14-2024 |
$9.46 | $9.22 | $9.46 | $9.755 | $9.08 | 2,000,971 | 06-13-2024 |
$8.82 | $9.15 | $8.82 | $9.57 | $8.59 | 1,187,984 | 06-12-2024 |
$9 | $8.64 | $9 | $9.27 | $8.46 | 1,822,554 | 06-11-2024 |
$9 | $7.765 | $9 | $9.4 | $7.66 | 3,612,013 | 06-10-2024 |
$7.9 | $7.26 | $7.9 | $8.04 | $6.696 | 2,622,480 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA fi...
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Gold...
2024-06-07 07:00:05 ET Robert Burns from H.C. Wainwright issued a price target of $17.00 for REPL on 2024-06-07 06:07:00. The adjusted price target was set to $17.00. At the time of the announcement, REPL was trading at $7.11. The overall price target consensus is at $26...